Recro Pharma Acquires Neuromuscular Blocking Agents

Recro Pharma (NASDAQ:REPH) announced the acquisition of exclusive global rights to two novel neuromuscular blocking agents and a proprietary chemical reversal agent from Cornell University.
As quoted in the press release:

The assets include one novel intermediate-acting neuromuscular blocking agent that has completed Phase I trials, one short-acting neuromuscular blocking agent, as well as a rapid-acting reversal agent proprietary to these compounds. The novel neuromuscular blocking agents acquired through this agreement permit a very rapid induction of neuromuscular blockade at the onset of use and the novel reversal agent will provide for more rapid reversal of the neuromuscular blockade. These novel agents may meaningfully reduce the patient’s post-procedure time in the operating room or post-acute care unit and could provide valuable cost savings to hospitals and ambulatory surgical centers.

“Cornell University is pleased to have licensed a series of proprietary neuromuscular blocking drugs to Recro Pharma Inc. and we look forward to working with them to commercialize this much needed technology for the benefit of patients and the medical community,” said Dr. Brian Kelly, the Director of Cornell’s Center for Technology Licensing at Cornell University.

Click here to read the full press release.

Source: globenewswire.com